Government Action/Industry Reaction: HHS Sees Success In Approach To Drug Pricing Solutions
Executive Summary
US HHS officials Azar and O’Brien tell a National Academy of Medicine forum that an important element of the Trump Administration’s approach to lowering drug prices is eliciting voluntary change from market players.
You may also be interested in...
Trump Administration's Rx-Price-Disclosure Reg Sets Up Legal Fight With PhRMA
From kinds of ads targeted to agency that's issuing the reg, policy seems designed to withstand a court challenge.
PhRMA’s Defensive Move On DTC Ads: Putting Drug List Prices ‘In Context’
Member companies’ direct-to-consumer TV ads will direct patients to information about drug costs – including list price, estimated out-of-pocket costs for the drug, and availability of financial assistance – under a voluntary program that takes effect in April 2019; initiative falls short of mandatory list price disclosures proposed by Trump Administration.
Step Therapy For Anti-Inflammatories, ESAs Coming To UnitedHealthcare Medicare Plans
Remicade, Procrit, Aranesp and biosimilars will be subject to step therapy in limited number of Medicare Advantage plans in 2019.